BILOPAQUE
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BILOPAQUE is an oral capsule diagnostic agent approved in 1969 by GE HealthCare, used as a radiographic contrast medium for gastrointestinal imaging. The product enables visualization of the biliary and digestive tract during diagnostic procedures. Its mechanism involves radio-opaque properties that enhance imaging contrast in fluoroscopy and radiological examinations.
LOE Approaching
Declining product nearing loss of exclusivity with minimal competitive differentiation and likely reduced headcount needs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BILOPAQUE presents minimal career opportunity with zero linked job openings and declining commercial relevance due to technological obsolescence in diagnostic imaging. Assignment to this legacy product typically indicates lower career trajectory unless focused on portfolio lifecycle management or GE HealthCare's diagnostic transition strategy.
Brand ManagerField Sales Representative
Worked on BILOPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.